Summary:
The study will evaluate the efficacy and safety of ITI-007 in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode.
Qualified Participants Must:
• Be between 18 and 65 years of age
•
Have a clinical diagnosis of Bipolar I or Bipolar II disorder
•
Be experiencing a current major depressive episode
Qualified Participants May Receive:
study-related medical care and investigational medication at no cost and may be compensated for time and travel.